Anti-tumor necrosis factor-α response in rheumatoid arthritis is associated with an increase in serum soluble CD30

Journal of Rheumatology

Volumn 35, Issue 1, 2008, Pages 14-19

  Gerli, Roberto ^a,e   Lunardi, Claudio ^b   Bocci, Elena Bartoloni ^a   Bobbio Pallavicini, Francesca ^c   Schillaci, Giuseppe ^a   Caporali, Roberto ^c   Bistoni, Onelia ^a   Pirro, Matteo ^a   Pitzalis, Costantino ^d   Montecucco, Carlomaurizio ^c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e POLICLINICO MONTELUCE   (Italy)

Author keywords

Anti tumor necrosis factor ; CD30; Infliximab; Rheumatoid arthritis; T cells

Indexed keywords

CD30 ANTIGEN; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SOLUBLE CD30 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; ITALY; LONGITUDINAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; T LYMPHOCYTE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38149082633     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995;85:1-14.
2. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998;10:457-70.
3. Gerli R, Lunardi C, Vinante F, et al. Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol 2001;22:72-7.
4. Gerli R, Muscat C, Bistoni O, et al. High levels of the soluble form of CD30 molecule in rheumatoid arthritis are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol 1995;102:547-50.
5. Del Prete G, De Carli M, Almerigogna F, et al. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J 1995;9:81-6.
6. D'Elios MM, Romagnani P, Scaletti C, et al. In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells. J Leukoc Biol 1997;61:539-44.
7. Gerli R, Lunardi C, Pitzalis C. Unmasking the anti-inflammatory cytokine response in rheumatoid synovitis. Rheumatology Oxford 2002;41:1341-5.
8. Toh ML, Miossec P. The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol 2007;19:284-8.
9. Gerli R, Pitzalis C, Bistoni O, et al. CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role. J Immunol 2000;164:4399-407.
10. Gerli R, Bistoni O, Russano A, et al. In vivo activated T cells in rheumatoid synovitis. Analysis of Th1- and Th2-type cytokine production at clonal level in different stages of disease. Clin Exp Immunol 2002;129:549-55.
11. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
12. Feldmann M, Maini RN. Anti-TNF-a therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;55:211-6.
13. Rigby WFC. Distinct mechanisms of action of tumor necrosis factor antagonists: what are the clinical implications? Semin Arthritis Rheum 2005;Suppl 5:1-2.
14. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevac EM, Lipsky PE. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006;108:253-61.
15. Shen C, Maerten P, Geboes K, et al. Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin Immunol 2005;115:250-9.
16. Schuerwegh AJ, Van Offel JF, Stevens WJ, et al. Influence of therapy with chimeric monoclonal tumor necrosis factor-a antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients. Rheumatology Oxford 2003;42:541-8.
17. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF-a therapy. J Exp Med 2004;200:277-85.
18. Toubi E, Kessel A, Mahmudov Z, Hallas K, Rozenbaum M, Rosner I. Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab. Ann NY Acad Sci 2005;1051:506-14.
19. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007;204:33-9.
20. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. Van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
22. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
23. Okamoto A, Yamamura M, Iwahashi M, et al. Pathophysiological functions of CD30+ CD4+ T cells in rheumatoid arthritis. Acta Med Okayama 2003;57:267-77.
24. Kennedy MK, Willis CR, Armitage RJ. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 2006;118:143-52.
25. Wiley SR, Goodwin RG, Smith CA. Reverse signaling via CD30 ligand. J Immunol 1996;157:3635-9.
26. Muta H, Boise LH, Fang L, et al. CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. J Immunol 2000;165:5105-11.
27. Opat S, Gaston JSH. CD30:CD30 ligand interactions in the immune response. Autoimmunity 2000;33:45-60.
28. Hargreaves PG, Al-Shamkhani A. Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signalling by CD30. Eur J Immunol 2002;32:163-73.
29. Saraiva M, Smith P, Fallon PG, et al. Inhibition of type 1 cytokine-mediated inflammation by a sCD30 homologue encoded by Ectromelia (Mousepox) virus. J Exp Med 2002;196:829-39.
30. Bobbio-Pallavicini F, Alpini C, Caporali R, et al. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004;6:R264-72.
31. De Rycke L, Verhelst X, Kruithof E, et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2005;64:299-302.
32. Alessandri C, Bombardieri M, Papa N, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFa therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004;3:1218-21.
33. Conway JG, Andrews RC, Beaudet B, et al. Inhibition of tumor necrosis factor-a (TNF-a) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-a-converting enzyme and matrix metalloproteinases. J Pharmacol Exp Ther 2001;298:900-8.
34. Hansen HP, Dietrich S, Kisseleva T, et al. CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-a-converting enzyme. J Immunol 2000;165:6703-9.
35. von Tresckow B, Kallen KJ, von Strandmann EP, et al. Depletion of cellular cholesterol and lipid rafts increases shedding of CD30. J Immunol 2004;172:4324-31.
36. Irace C, Mancuso G, Fiaschi E, et al. Effect of anti-TNFa therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 2004;177:113-8.
37. de Kleer IM, Kamphuis SM, Rijkers GT, et al. The spontaneous remission of juvenile idiopathic arthritis is characterized by CD30+ T cells directed to human heat-shock protein 60 capable of producing the regulatory cytokine interleukin-10. Arthritis Rheum 2003;48:2001-10.
38. Gerli R, Bistoni O, Lunardi C, et al. Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy. Rheumatology Oxford 1999;38:1282-4.